CN102319432B - 由双挤压法制备的眼植入物 - Google Patents
由双挤压法制备的眼植入物 Download PDFInfo
- Publication number
- CN102319432B CN102319432B CN201110225755.8A CN201110225755A CN102319432B CN 102319432 B CN102319432 B CN 102319432B CN 201110225755 A CN201110225755 A CN 201110225755A CN 102319432 B CN102319432 B CN 102319432B
- Authority
- CN
- China
- Prior art keywords
- implant
- dexamethasone
- release
- purposes
- active agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Prostheses (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/918,597 US20050048099A1 (en) | 2003-01-09 | 2004-08-13 | Ocular implant made by a double extrusion process |
US10/918,597 | 2004-08-13 | ||
CN2005800273099A CN101083976B (zh) | 2004-08-13 | 2005-07-25 | 由双挤压法制备的眼植入物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800273099A Division CN101083976B (zh) | 2004-08-13 | 2005-07-25 | 由双挤压法制备的眼植入物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102319432A CN102319432A (zh) | 2012-01-18 |
CN102319432B true CN102319432B (zh) | 2016-12-21 |
Family
ID=35825444
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800273099A Active CN101083976B (zh) | 2004-08-13 | 2005-07-25 | 由双挤压法制备的眼植入物 |
CN200910224822.7A Active CN101721354B (zh) | 2004-08-13 | 2005-07-25 | 由双挤压法制备的眼植入物 |
CN201110225755.8A Active CN102319432B (zh) | 2004-08-13 | 2005-07-25 | 由双挤压法制备的眼植入物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800273099A Active CN101083976B (zh) | 2004-08-13 | 2005-07-25 | 由双挤压法制备的眼植入物 |
CN200910224822.7A Active CN101721354B (zh) | 2004-08-13 | 2005-07-25 | 由双挤压法制备的眼植入物 |
Country Status (25)
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060280774A1 (en) * | 1995-06-02 | 2006-12-14 | Allergan, Inc. | Compositions and methods for treating glaucoma |
US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
ES2250504T3 (es) | 2000-11-29 | 2006-04-16 | Allergan Inc. | Prevencion del rechazo de injerto en el ojo. |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
CN1934255B (zh) | 2003-08-27 | 2012-07-11 | 奥普索特克公司 | 用于治疗眼新血管疾病的组合治疗 |
US20070212395A1 (en) * | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
US20050244461A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Controlled release drug delivery systems and methods for treatment of an eye |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US20160106717A1 (en) | 2004-09-24 | 2016-04-21 | Gen Pharma Holdings LLC | Cai-based systems and methods for the localized treatment of uveitis |
US20060204548A1 (en) * | 2005-03-01 | 2006-09-14 | Allergan, Inc. | Microimplants for ocular administration |
BRPI0615962A2 (pt) | 2005-07-27 | 2011-05-31 | Univ Florida | uso de um composto selecionado do grupo que consiste em um inibidor proteassomal, um inibidor de autofagia, um inibidor lisossomal, um inibidor do trasporte de proteìna do er ao golgi, um inibidor de chaperonina hsp90, um ativador da resposta a choque térmico, um inibidor de glicosidade, e um inibidor de histona deacetilase, uso de 11-cis-retinal ou 9-cis-retinal e um composto selecionado do grupo que consiste em um inibidor proteassomal, um inibidor de autofagia, um inibidor lissosomal, um inibidor do transporte de proteìna do er ao golgi, um inibidor de chaperonina hsp90, um ativador de resposta a choque térmico, um inibidor de glicosidase, e um inibidor de histona deacetilase, método para aumentar a quantidade de um conformação bioquimicamente funcional de uma proteìna em uma célula, composição farmacêutica para o tratamento de um pcd ocular, composição farmacêutica para o tratamento de retinite pigmentosa, kit para o tratamento de um pcd ocular, kit para o tratamento de retinite pigmentosa, método para a identificação de um composto útil para o tratamento de um indivìduo que tem um pcd ocular, método para a identificação de um composto útil para o tratamento de um indivìduo que tem retinite pigmentosa, uso de um inibidor proteassomal ou um inibidor de autofagia e método para a produção de uma proteìna recombinante em uma conformação bioquimicamente funcional |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
NZ562032A (en) * | 2005-10-18 | 2011-11-25 | Allergan Inc | Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues |
US8236904B2 (en) * | 2005-12-28 | 2012-08-07 | Ethicon, Inc. | Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates |
US7756524B1 (en) | 2006-01-31 | 2010-07-13 | Nextel Communications Inc. | System and method for partially count-based allocation of vocoder resources |
US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
CN101505696B (zh) * | 2006-06-21 | 2012-11-14 | 庄臣及庄臣视力保护公司 | 用于递送活性试剂的泪点塞 |
US8802128B2 (en) | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
BRPI0715467A2 (pt) * | 2006-07-11 | 2013-03-12 | Refocus Group Inc | pràtese escleral para tratamento de presbiopia e outras doenÇas oculares e dispositivo e mÉtodos relacionados |
US8911496B2 (en) | 2006-07-11 | 2014-12-16 | Refocus Group, Inc. | Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods |
US8846073B2 (en) | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
US8231892B2 (en) | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
CN104288844A (zh) * | 2007-10-18 | 2015-01-21 | 杜雷科特公司 | 具有可控堆积密度的可生物降解植入物 |
CA2705239C (en) * | 2007-11-08 | 2018-09-25 | Alimera Sciences, Inc. | Ocular implantation device |
GB0722484D0 (en) * | 2007-11-15 | 2007-12-27 | Ucl Business Plc | Solid compositions |
US20090196905A1 (en) * | 2008-02-06 | 2009-08-06 | Spada Lon T | Stabilization of mitochondrial membranes in ocular diseases and conditions |
JP2011513337A (ja) * | 2008-04-18 | 2011-04-28 | ウォーソー・オーソペディック・インコーポレーテッド | 椎間板ヘルニアを治療するための方法および組成物 |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US8557273B2 (en) * | 2008-04-18 | 2013-10-15 | Medtronic, Inc. | Medical devices and methods including polymers having biologically active agents therein |
US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
WO2009140246A2 (en) | 2008-05-12 | 2009-11-19 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US20100098772A1 (en) * | 2008-10-21 | 2010-04-22 | Allergan, Inc. | Drug delivery systems and methods for treating neovascularization |
CA2744245A1 (en) * | 2008-11-19 | 2010-05-27 | Refocus Group, Inc. | Artificial intraocular lens, altered natural crystalline lens, or refilled natural crystalline lens capsule with one or more scleral prostheses for improved performance |
US20100204325A1 (en) * | 2009-02-11 | 2010-08-12 | Allergan, Inc. | Valproic acid drug delivery systems and intraocular therapeutic uses thereof |
US20100239632A1 (en) | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
CN104887388B (zh) | 2009-06-03 | 2018-01-09 | 弗赛特影像5股份有限公司 | 前段药物输送 |
IN2012DN00352A (US08034370-20111011-C00001.png) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
TW201105363A (en) | 2009-07-14 | 2011-02-16 | Univ Yamagata | Eye drop for macular edema treatment |
WO2011041373A1 (en) * | 2009-09-29 | 2011-04-07 | Eyegate Pharmaceuticals, Inc. | Positively-charged poly (d,l-lactide-co-glycolide) nanoparticles and fabrication methods of the same |
MX361709B (es) | 2009-11-09 | 2018-12-07 | Allergan Inc | Composiciones y metodos para estimular el crecimiento del cabello. |
DE102010014113A1 (de) * | 2010-04-07 | 2011-10-13 | Acino Ag | Freisetzungsverfahren für Implantate |
WO2011133370A1 (en) * | 2010-04-23 | 2011-10-27 | Medtronic, Inc. | Shelf stable pharmaceutical depot |
US9370444B2 (en) | 2010-10-12 | 2016-06-21 | Emmett T. Cunningham, JR. | Subconjunctival conformer device and uses thereof |
US8915877B2 (en) | 2010-10-12 | 2014-12-23 | Emmett T. Cunningham, JR. | Glaucoma drainage device and uses thereof |
WO2012068247A1 (en) | 2010-11-16 | 2012-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for treatment of dry eye |
US9821159B2 (en) | 2010-11-16 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Stimulation devices and methods |
US9005634B2 (en) | 2011-04-13 | 2015-04-14 | Medtronic, Inc. | Shelf stable pharmaceutical depot |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
JP6068457B2 (ja) | 2011-06-14 | 2017-01-25 | ビカム ファーマスーティカルス,インコーポレイテッド | 化合物及び組成物 |
JP5989780B2 (ja) | 2011-09-14 | 2016-09-07 | フォーサイト・ビジョン5・インコーポレイテッドForsight Vision5,Inc. | 眼挿入装置および方法 |
AU2012346214B2 (en) | 2011-11-30 | 2017-09-14 | Bikam Pharmaceuticals, Inc. | Opsin-binding ligands, compositions and methods of use |
US10040749B2 (en) | 2011-12-01 | 2018-08-07 | Bikam Pharmaceuticals Inc. | Opsin-binding ligands, compositions and methods of use |
GB201120771D0 (en) * | 2011-12-02 | 2012-01-11 | Ljt Projects Ltd | tear duct resistance measuring system |
US8945214B2 (en) | 2011-12-19 | 2015-02-03 | Allergan, Inc. | Intravitreal applicator |
US10675376B2 (en) * | 2012-05-24 | 2020-06-09 | Ethicon Llc | Mechanically strong absorbable polymeric blend compositions of precisely controllable absorption rates, processing methods, and products therefrom |
US10653621B2 (en) * | 2012-09-27 | 2020-05-19 | Allergan, Inc. | Biodegradable drug delivery systems for the sustained release of proteins |
WO2014066775A1 (en) | 2012-10-26 | 2014-05-01 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
DK3660033T5 (da) | 2012-11-15 | 2022-06-27 | Apellis Pharmaceuticals Inc | Langtidsvirkende compstatinanaloger og tilhørende sammensætninger og fremgangsmåder |
US10993834B2 (en) | 2013-01-15 | 2021-05-04 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal system drug delivery device |
WO2014127243A1 (en) | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Sustained drug delivery implant |
JP6408492B2 (ja) | 2013-02-18 | 2018-10-17 | ヴェジェニクス プロプライエタリー リミテッドVegenics Pty Limited | リガンド結合分子およびその使用 |
EP2967817B1 (en) | 2013-03-12 | 2021-03-10 | Oculeve, Inc. | Implant delivery devices and systems |
WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
RU2015146211A (ru) * | 2013-04-01 | 2017-05-19 | Аллерган, Инк. | Микросферная система доставки лекарственного средства для замедленного внутриглазного высвобождения |
US10155108B2 (en) | 2013-04-19 | 2018-12-18 | Oculeve, Inc. | Nasal stimulation devices and methods |
MX2016000364A (es) | 2013-07-12 | 2016-05-09 | Ophthotech Corp | Metodos para tratar o prevenir afecciones oftalmologicas. |
US20150114855A1 (en) * | 2013-10-24 | 2015-04-30 | Aaren Scientific Inc. | Hydrophilic iol packaging system |
SG10201809363SA (en) | 2013-11-15 | 2018-11-29 | Allergan Inc | Methods of treatment of ocular conditions with a sustained drug delivery implant |
KR20160091960A (ko) * | 2013-11-27 | 2016-08-03 | 에티컨, 엘엘씨 | 정밀하게 제어가능한 흡수 속도를 갖는 흡수성 중합체 블렌드 조성물, 가공 방법, 및 그로부터의 치수 안정한 의료 장치 |
CN106470673B (zh) | 2014-02-25 | 2020-01-31 | 奥库利维公司 | 用于鼻泪刺激的聚合物制剂 |
RU2557925C1 (ru) * | 2014-03-17 | 2015-07-27 | Новиков Сергей Викторович | Биодеградируемый многослойный имплант для введения лекарственных веществ в витреальную полость глаза |
US20150342875A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US9687652B2 (en) | 2014-07-25 | 2017-06-27 | Oculeve, Inc. | Stimulation patterns for treating dry eye |
CN104164505B (zh) * | 2014-08-08 | 2016-01-13 | 重庆医科大学附属第一医院 | 一种用于检测vkh综合征的试剂盒 |
JP6819908B2 (ja) * | 2014-09-19 | 2021-01-27 | オクラー リミテッド | 眼科用医薬組成物 |
WO2016065215A1 (en) | 2014-10-22 | 2016-04-28 | Oculeve, Inc. | Stimulation devices and methods for treating dry eye |
AU2015335772B2 (en) | 2014-10-22 | 2020-07-09 | Oculeve, Inc. | Contact lens for increasing tear production |
EP3209371A4 (en) | 2014-10-22 | 2018-10-24 | Oculeve, Inc. | Implantable nasal stimulator systems and methods |
EP3283004A4 (en) | 2015-04-13 | 2018-12-05 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
JP6968787B2 (ja) | 2015-10-07 | 2021-11-17 | アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. | 投与レジメン |
CA3006042A1 (en) | 2015-11-23 | 2017-06-01 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal system for drug delivery |
US10426958B2 (en) | 2015-12-04 | 2019-10-01 | Oculeve, Inc. | Intranasal stimulation for enhanced release of ocular mucins and other tear proteins |
US10252048B2 (en) | 2016-02-19 | 2019-04-09 | Oculeve, Inc. | Nasal stimulation for rhinitis, nasal congestion, and ocular allergies |
US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
CA3022683A1 (en) | 2016-05-02 | 2017-11-09 | Oculeve, Inc. | Intranasal stimulation for treatment of meibomian gland disease and blepharitis |
WO2017201255A1 (en) | 2016-05-20 | 2017-11-23 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal drug delivery device |
KR20190124698A (ko) | 2016-12-02 | 2019-11-05 | 오큘레브, 인크. | 건성안 예측 및 치료 권고를 위한 장치 및 방법 |
US11273072B2 (en) | 2017-01-13 | 2022-03-15 | Gyroscope Therapeutics Limited | Suprachoroidal injection device |
WO2018187813A1 (en) | 2017-04-07 | 2018-10-11 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
BR112020004983A2 (pt) | 2017-09-15 | 2020-09-15 | Oxular Limited | dispositivo de canulação para administrar um agente ativo que contém composição a um olho, método para o tratamento de uma doença ou afecção pela entrega de um material líquido ou semissólido para a região afetada, método para o tratamento de uma doença ou afecção ocular por meio da injeção de um material sólido ou semissólido para o espaço supracoroide ou espaço supraciliar e método para a injeção de um materiço supracoroide ou espaço supraciliar pelo uso do dispositivoal no espa |
CN109265458B (zh) * | 2018-11-12 | 2020-09-15 | 中国医学科学院药用植物研究所 | 一种基于苦参碱的抗肿瘤药物化合物 |
CN109464705B (zh) * | 2018-11-19 | 2021-08-17 | 爱尔眼科医院集团股份有限公司 | 一种rpe细胞片及其应用和制备方法 |
US11039954B2 (en) | 2019-03-21 | 2021-06-22 | Microoptx Inc. | Implantable ocular drug delivery devices and methods |
WO2020227407A1 (en) * | 2019-05-07 | 2020-11-12 | Cornell University | Temporary synthetic carrier for corneal tissue insertion and tissue delivery |
MX2021015760A (es) | 2019-06-27 | 2022-04-06 | Layerbio Inc | Sistemas de administracion de medicamentos de dispositivos oculares. |
WO2021154589A1 (en) * | 2020-01-28 | 2021-08-05 | Merck Sharp & Dohme Corp. | Drug delivery system for the delivery of steroid to vitreous chamber of the eye |
CN114533648A (zh) * | 2020-11-26 | 2022-05-27 | 成都康弘药业集团股份有限公司 | 一种阿西替尼眼内植入剂 |
US20220233564A1 (en) * | 2021-01-25 | 2022-07-28 | University Of South Florida | Ophthalmological formulations for the prevention of a coronavirus infection |
US20240042713A1 (en) * | 2021-12-06 | 2024-02-08 | Ocular Therapeutix, Inc. | Extruded ocular inserts or implants and methods thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773021A (en) * | 1994-03-14 | 1998-06-30 | Vetoquinol S.A. | Bioadhesive ophthalmic insert |
WO2002043785A2 (en) * | 2000-11-29 | 2002-06-06 | Oculex Pharmaceuticals, Inc. | Intraocular implants for preventing transplant rejection in the eye |
US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
US20040137059A1 (en) * | 2003-01-09 | 2004-07-15 | Thierry Nivaggioli | Biodegradable ocular implant |
Family Cites Families (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL297357A (US08034370-20111011-C00001.png) * | 1962-08-31 | |||
US3416530A (en) | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
US3986510A (en) * | 1971-09-09 | 1976-10-19 | Alza Corporation | Bioerodible ocular device |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3914402A (en) * | 1973-06-14 | 1975-10-21 | Alza Corp | Ophthalmic dosage form, for releasing medication over time |
SE390255B (sv) * | 1974-02-18 | 1976-12-13 | N G Y Torphammar | Upprullningsanordning foretredesvis for ett sekerhetsbelte i ett fordon |
US3961628A (en) * | 1974-04-10 | 1976-06-08 | Alza Corporation | Ocular drug dispensing system |
US3921632A (en) | 1974-08-16 | 1975-11-25 | Frank M Bardani | Implant device |
GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4180646A (en) | 1975-01-28 | 1979-12-25 | Alza Corporation | Novel orthoester polymers and orthocarbonate polymers |
US4144317A (en) * | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
US4014334A (en) * | 1976-02-02 | 1977-03-29 | Alza Corporation | Laminated osmotic system for dispensing beneficial agent |
US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
US4201210A (en) * | 1976-06-22 | 1980-05-06 | The United States Of America As Represented By The Secretary Of Agriculture | Veterinary ocular ring device for sustained drug release |
US4186184A (en) * | 1977-12-27 | 1980-01-29 | Alza Corporation | Selective administration of drug with ocular therapeutic system |
US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4300557A (en) | 1980-01-07 | 1981-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating intraocular malignancies |
US4402979A (en) * | 1980-03-21 | 1983-09-06 | Merck & Co., Inc. & Laboratories | Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid |
US4304765A (en) | 1980-10-14 | 1981-12-08 | Alza Corporation | Ocular insert housing steroid in two different therapeutic forms |
DE3168032D1 (en) | 1980-11-10 | 1985-02-14 | Alza Corp | Erodible polymer containing erosion rate modifier |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
JPS58126435U (ja) * | 1982-02-19 | 1983-08-27 | オリンパス光学工業株式会社 | Ttlオ−トストロボ用絞り制御回路 |
US4451254A (en) * | 1982-03-15 | 1984-05-29 | Eli Lilly And Company | Implant system |
US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
DE3220156C2 (de) * | 1982-05-28 | 1990-01-25 | Heida Houston Tex. Thurlow | Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
IT1229075B (it) | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico |
US4521210A (en) * | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
US4478818A (en) * | 1982-12-27 | 1984-10-23 | Alza Corporation | Ocular preparation housing steroid in two different therapeutic forms |
US6309669B1 (en) * | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
US6217911B1 (en) * | 1995-05-22 | 2001-04-17 | The United States Of America As Represented By The Secretary Of The Army | sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres |
CN100391445C (zh) | 1996-01-24 | 2008-06-04 | 美国政府陆军部 | 新型的“非突发的”持续释放聚(丙交酯/乙交酯)的微球 |
US4629621A (en) * | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
US5082655A (en) * | 1984-07-23 | 1992-01-21 | Zetachron, Inc. | Pharmaceutical composition for drugs subject to supercooling |
US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
US4966849A (en) * | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
DE3612212A1 (de) * | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
US4756911A (en) * | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4959217A (en) * | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
US5322691A (en) * | 1986-10-02 | 1994-06-21 | Sohrab Darougar | Ocular insert with anchoring protrusions |
US4863457A (en) * | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
US5006342A (en) * | 1986-12-22 | 1991-04-09 | Cygnus Corporation | Resilient transdermal drug delivery device |
DE3734223A1 (de) | 1987-10-09 | 1989-04-20 | Boehringer Ingelheim Kg | Implantierbares, biologisch abbaubares wirkstofffreigabesystem |
US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
US4945089A (en) * | 1987-12-29 | 1990-07-31 | Alcon Laboratories, Inc. | Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids |
US4865846A (en) * | 1988-06-03 | 1989-09-12 | Kaufman Herbert E | Drug delivery system |
GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
DE03014533T1 (de) | 1988-09-06 | 2004-07-15 | Pharmacia Ab | Prostaglandinderivative zur Behandlung von Glaukom oder okuläre Hypertension |
US5004601A (en) * | 1988-10-14 | 1991-04-02 | Zetachron, Inc. | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith |
US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
US5034413A (en) * | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
US5028624A (en) * | 1989-07-27 | 1991-07-02 | Allergan, Inc. | Intraocular pressure reducing 9,15-diacyl prostaglandins |
SG49267A1 (en) * | 1989-08-14 | 1998-05-18 | Photogenesis Inc | Surgical instrument and cell isolation and transplantation |
US5112614A (en) * | 1989-09-14 | 1992-05-12 | Alza Corporation | Implantable delivery dispenser |
US5268178A (en) | 1989-09-25 | 1993-12-07 | The Board Of Regents, The University Of Texas System | Biodegradable antibiotic implants and methods of their use in treating and preventing infections |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
US5660851A (en) * | 1989-12-26 | 1997-08-26 | Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem | Ocular inserts |
US5175235A (en) | 1990-06-04 | 1992-12-29 | Nova Pharmaceutical Corporation | Branched polyanhydrides |
US5075115A (en) | 1990-04-02 | 1991-12-24 | Fmc Corporation | Process for polymerizing poly(lactic acid) |
US5326905A (en) | 1990-04-02 | 1994-07-05 | Pfizer Inc. | Benzylphosphonic acid tyrosine kinase inhibitors |
EP0474098B1 (en) | 1990-08-30 | 1994-03-02 | Senju Pharmaceutical Co., Ltd. | Controlled drug release composition |
KR0185215B1 (ko) * | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
CA2108889A1 (en) | 1991-05-29 | 1992-11-30 | Robert Lee Dow | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
WO1993000050A1 (en) * | 1991-06-21 | 1993-01-07 | Genetics Institute, Inc. | Pharmaceutical formulations of osteogenic proteins |
US5356629A (en) * | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
US5169638A (en) | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
CA2425849C (en) | 1991-11-22 | 2007-02-27 | Alcon Laboratories, Inc. | Angiostatic steroids |
US5543154A (en) * | 1991-12-27 | 1996-08-06 | Merck & Co., Inc. | Controlled release nifedipine delivery device |
US6045791A (en) * | 1992-03-06 | 2000-04-04 | Photogenesis, Inc. | Retinal pigment epithelium transplantation |
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
US5384333A (en) * | 1992-03-17 | 1995-01-24 | University Of Miami | Biodegradable injectable drug delivery polymer |
US5178635A (en) | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
JPH08503450A (ja) | 1992-08-06 | 1996-04-16 | ワーナー−ランバート・コンパニー | 蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する2−チオインドール(セレノインドール)および関連ジスルフィド(セレニド) |
US5922340A (en) * | 1992-09-10 | 1999-07-13 | Children's Medical Center Corporation | High load formulations and methods for providing prolonged local anesthesia |
US5972991A (en) * | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
AU687727B2 (en) | 1992-10-28 | 1998-03-05 | Genentech Inc. | Vascular endothelial cell growth factor antagonists |
US5314419A (en) * | 1992-10-30 | 1994-05-24 | Pelling George E | Method for dispensing ophthalmic drugs to the eye |
ATE183083T1 (de) * | 1992-11-18 | 1999-08-15 | Fujisawa Pharmaceutical Co | Pharmazeutische zubereitung mit verlängerter wirkung |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US5538735A (en) | 1993-02-19 | 1996-07-23 | Ahn; Sam S. | Method of making a drug delivery system using hollow fibers |
JP3000187B2 (ja) * | 1993-02-26 | 2000-01-17 | 参天製薬株式会社 | 生体分解性強膜プラグ |
WO1994018921A1 (fr) | 1993-02-26 | 1994-09-01 | Santen Pharmaceutical Co., Ltd. | Bouchon de sclerotique biodegradable |
US5707643A (en) * | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US6051576A (en) * | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
DE4403326C1 (de) * | 1994-02-03 | 1995-06-22 | Hans Reinhard Prof Dr Koch | Intraokulare Linsenanordnung zur Astigmatismuskorrektur |
US6586006B2 (en) * | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
US5755785A (en) * | 1994-08-12 | 1998-05-26 | The University Of South Florida | Sutureless corneal transplantation method |
US6063116A (en) * | 1994-10-26 | 2000-05-16 | Medarex, Inc. | Modulation of cell proliferation and wound healing |
US6369116B1 (en) * | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US5693335A (en) | 1995-06-07 | 1997-12-02 | Cygnus, Inc. | Skin permeation enhancer composition for use with sex steroids |
US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
JP3345428B2 (ja) * | 1996-08-20 | 2002-11-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 合成甲状腺ホルマン組成物を使用した眼の処置 |
US6046187A (en) * | 1996-09-16 | 2000-04-04 | Children's Medical Center Corporation | Formulations and methods for providing prolonged local anesthesia |
JP2002514194A (ja) | 1996-11-19 | 2002-05-14 | ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド | 角膜移植拒否又は眼疾におけるil―1raの局所使用 |
US5941250A (en) * | 1996-11-21 | 1999-08-24 | University Of Louisville Research Foundation Inc. | Retinal tissue implantation method |
US20020111603A1 (en) | 1996-12-02 | 2002-08-15 | Societe De Conseils De Recherches Et D'application | Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process |
ATE333266T1 (de) * | 1997-03-31 | 2006-08-15 | Alza Corp | Diffusionsgesteuertes implantierbares verabreichungssystem |
JPH1170138A (ja) * | 1997-07-02 | 1999-03-16 | Santen Pharmaceut Co Ltd | ポリ乳酸強膜プラグ |
EP0992244A4 (en) | 1997-07-02 | 2001-01-17 | Santen Pharmaceutical Co Ltd | SCLERAL PLUGS OF POLYLACTIC ACID |
US6306426B1 (en) | 1997-08-11 | 2001-10-23 | Allergan Sales, Inc. | Implant device with a retinoid for improved biocompatibility |
EP1003569B1 (en) * | 1997-08-11 | 2004-10-20 | Allergan, Inc. | Sterile bioerodible implant device containing retinoid with improved biocompatability and method of manufacture |
US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
US6329369B1 (en) | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
US6196993B1 (en) | 1998-04-20 | 2001-03-06 | Eyelab Group, Llc | Ophthalmic insert and method for sustained release of medication to the eye |
EP1104302A4 (en) | 1998-07-10 | 2006-08-09 | Retmed Pty Ltd | PROPHYLACTIC TREATMENTS OF BLOOD VESSEL NEOFORMATION IN MACULAR DEGENERATION |
US6406498B1 (en) | 1998-09-04 | 2002-06-18 | Bionx Implants Oy | Bioactive, bioabsorbable surgical composite material |
CA2351734A1 (en) | 1998-11-20 | 2000-06-02 | University Of Connecticut | Generic integrated implantable potentiostat telemetry unit for electrochemical sensors |
US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
AU7711800A (en) | 1999-09-23 | 2001-04-24 | Sloan-Kettering Institute For Cancer Research | Novel uses of 2-bromopalmitate |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6579533B1 (en) * | 1999-11-30 | 2003-06-17 | Bioasborbable Concepts, Ltd. | Bioabsorbable drug delivery system for local treatment and prevention of infections |
US6545182B2 (en) * | 2000-04-13 | 2003-04-08 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
US7335803B2 (en) * | 2001-10-19 | 2008-02-26 | Allergan, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
US20040208910A1 (en) | 2000-04-26 | 2004-10-21 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of adrenergic agents |
US20040170665A1 (en) * | 2000-06-02 | 2004-09-02 | Allergan, Inc. | Intravitreal botulinum toxin implant |
EP1550471A1 (en) | 2000-11-29 | 2005-07-06 | Allergan Inc. | Intraocular implants for preventing transplant rejection in the eye |
US6534542B2 (en) * | 2001-02-27 | 2003-03-18 | Allergen Sales, Inc. | (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors |
US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
US7056339B2 (en) * | 2001-04-20 | 2006-06-06 | The Board Of Trustees Of The Leland Stanford Junior University | Drug delivery platform |
WO2002089767A1 (en) | 2001-05-03 | 2002-11-14 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
EP1408876A4 (en) * | 2001-06-22 | 2004-09-22 | Durect Corp | ZERO ORDER COAXIAL IMPLANTS WITH EXTENDED RELEASE |
US7282216B2 (en) * | 2001-11-12 | 2007-10-16 | Alkermes Controlled Therapeutics, Inc. | Biocompatible polymer blends and uses thereof |
US6541504B1 (en) * | 2002-04-03 | 2003-04-01 | Allergan Sales, Llc | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
AU2003234439A1 (en) | 2002-05-07 | 2003-11-11 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
US20040266776A1 (en) | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
US7276522B2 (en) | 2002-05-21 | 2007-10-02 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7345065B2 (en) * | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7468065B2 (en) | 2002-09-18 | 2008-12-23 | Allergan, Inc. | Apparatus for delivery of ocular implants |
TWI282271B (en) | 2002-09-18 | 2007-06-11 | Allergan Inc | Apparatus for delivery of ocular implants |
US6899717B2 (en) | 2002-09-18 | 2005-05-31 | Allergan, Inc. | Methods and apparatus for delivery of ocular implants |
ATE418323T1 (de) * | 2002-11-06 | 2009-01-15 | Alza Corp | Depot-formulierungen mit verzögerter freisetzung |
US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
CA2513752C (en) * | 2003-01-24 | 2012-01-03 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors |
US7141597B2 (en) | 2003-09-12 | 2006-11-28 | Allergan, Inc. | Nonsedating α-2 agonists |
US20050059664A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
US20050058696A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US20050059744A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
JP2007518804A (ja) * | 2004-01-20 | 2007-07-12 | アラーガン、インコーポレイテッド | トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物 |
US7691381B2 (en) | 2004-04-15 | 2010-04-06 | Allergan, Inc. | Stabilized biodegradable neurotoxin implants |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US20050244458A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
US20050244471A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
US7993634B2 (en) * | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
EP2216026B1 (en) * | 2004-07-12 | 2016-04-20 | Allergan, Inc. | Ophthalmic compositions and uses for treating ophthalmic conditions |
US20060204548A1 (en) | 2005-03-01 | 2006-09-14 | Allergan, Inc. | Microimplants for ocular administration |
US20060233857A1 (en) | 2005-04-14 | 2006-10-19 | Amsden Brian G | Degradable elastomeric network |
US20070260203A1 (en) | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
US20070298073A1 (en) | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
EP3000434A1 (en) | 2007-03-16 | 2016-03-30 | The Regents Of The University Of California | Nanostructure surface coated medical implants and methods of using the same |
US7740604B2 (en) | 2007-09-24 | 2010-06-22 | Ivantis, Inc. | Ocular implants for placement in schlemm's canal |
-
2004
- 2004-08-13 US US10/918,597 patent/US20050048099A1/en not_active Abandoned
-
2005
- 2005-07-25 CN CN2005800273099A patent/CN101083976B/zh active Active
- 2005-07-25 SI SI200530161T patent/SI1776091T1/sl unknown
- 2005-07-25 DE DE602005003957T patent/DE602005003957T2/de active Active
- 2005-07-25 EP EP05814028A patent/EP1776091B1/en active Active
- 2005-07-25 PT PT05814028T patent/PT1776091E/pt unknown
- 2005-07-25 NZ NZ552679A patent/NZ552679A/en unknown
- 2005-07-25 CN CN200910224822.7A patent/CN101721354B/zh active Active
- 2005-07-25 MX MX2007001538A patent/MX2007001538A/es active IP Right Grant
- 2005-07-25 EP EP10185774A patent/EP2329811B1/en not_active Revoked
- 2005-07-25 DK DK05814028T patent/DK1776091T3/da active
- 2005-07-25 PL PL05814028T patent/PL1776091T3/pl unknown
- 2005-07-25 RU RU2007103318/15A patent/RU2389479C2/ru active
- 2005-07-25 AU AU2005290240A patent/AU2005290240B2/en active Active
- 2005-07-25 ES ES10185774T patent/ES2414231T3/es active Active
- 2005-07-25 CA CA2576392A patent/CA2576392C/en active Active
- 2005-07-25 ES ES07017089T patent/ES2412881T3/es active Active
- 2005-07-25 CN CN201110225755.8A patent/CN102319432B/zh active Active
- 2005-07-25 PL PL382452A patent/PL382452A1/pl not_active IP Right Cessation
- 2005-07-25 KR KR1020137025447A patent/KR101451060B1/ko active IP Right Grant
- 2005-07-25 ES ES05814028T patent/ES2297766T3/es active Active
- 2005-07-25 AT AT05814028T patent/ATE381319T1/de active
- 2005-07-25 EP EP07017089A patent/EP1870092B1/en not_active Revoked
- 2005-07-25 BR BRPI0513849A patent/BRPI0513849B8/pt active Search and Examination
- 2005-07-25 KR KR1020077003441A patent/KR101365772B1/ko active IP Right Grant
- 2005-07-25 JP JP2007525641A patent/JP4949245B2/ja active Active
- 2005-07-25 WO PCT/US2005/026500 patent/WO2006036280A1/en active Search and Examination
- 2005-08-10 TW TW094127159A patent/TWI332846B/zh active
- 2005-08-12 AR ARP050103402A patent/AR051278A1/es not_active Application Discontinuation
-
2007
- 2007-01-22 IL IL180865A patent/IL180865A/en active IP Right Grant
- 2007-02-21 NO NO20070992A patent/NO342740B1/no unknown
- 2007-10-31 US US11/931,954 patent/US8034370B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/932,101 patent/US8034366B2/en not_active Expired - Fee Related
-
2008
- 2008-03-04 CY CY20081100251T patent/CY1107823T1/el unknown
- 2008-06-23 HK HK08106971.2A patent/HK1111912A1/xx not_active IP Right Cessation
- 2008-07-15 US US12/173,746 patent/US8048445B2/en not_active Expired - Fee Related
-
2010
- 2010-10-22 AU AU2010235967A patent/AU2010235967C1/en active Active
- 2010-12-05 IL IL209771A patent/IL209771A/en active IP Right Grant
-
2011
- 2011-08-19 US US13/213,473 patent/US8506987B2/en not_active Expired - Lifetime
- 2011-09-01 US US13/224,041 patent/US8318070B2/en not_active Expired - Lifetime
- 2011-10-19 HK HK11111214.4A patent/HK1156856A1/xx not_active IP Right Cessation
-
2013
- 2013-03-12 US US13/797,230 patent/US8778381B2/en not_active Expired - Lifetime
- 2013-06-20 US US13/922,482 patent/US9192511B2/en not_active Expired - Fee Related
-
2015
- 2015-11-23 US US14/949,454 patent/US10076526B2/en not_active Expired - Lifetime
-
2018
- 2018-09-17 US US16/132,857 patent/US10702539B2/en not_active Expired - Lifetime
-
2020
- 2020-06-29 US US16/915,017 patent/US20210113592A1/en not_active Abandoned
-
2022
- 2022-07-12 US US17/812,133 patent/US20230172948A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773021A (en) * | 1994-03-14 | 1998-06-30 | Vetoquinol S.A. | Bioadhesive ophthalmic insert |
US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
WO2002043785A2 (en) * | 2000-11-29 | 2002-06-06 | Oculex Pharmaceuticals, Inc. | Intraocular implants for preventing transplant rejection in the eye |
US20040137059A1 (en) * | 2003-01-09 | 2004-07-15 | Thierry Nivaggioli | Biodegradable ocular implant |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102319432B (zh) | 由双挤压法制备的眼植入物 | |
EP3563839A1 (en) | Biodegradable ocular implant | |
AU2018236685B2 (en) | Ocular implant made by a double extrusion process | |
AU2014201844B2 (en) | Ocular implant made by a double extrusion process | |
AU2012216644B2 (en) | Ocular implant made by a double extrusion process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |